CAPACITY DEVELOPMENT

Impactful TB trials require proactive leadership & recruitment at high-disease-burden sites.  Few African institutions possess sufficient capacity to evaluate new anti-TB regimens.

OptiRiMoxTB trial has been specifically designed to expand clinical trial capacity in four countries; KIDH (Tanzania), an experienced recruitment centre, is now assuming trial sponsor responsibility, CERMEL (Gabon), KUHeS (Malawi) & INS (Mozambique) have, via SimpliciTB, strengthened TB trial infrastructure and are now recruiting patients in all 4 sites.